Sagent buys U.S. sterile injectables plant in boost for parent Nichi-Iko

U.S.-based sterile injectables drugmaker Sagent Pharmaceutials, which traditionally relied on contractors, has picked up a biologics plant from Xellia Pharmaceuticals. Xellia still has a larger facility in Bedford, Ohio, that it bought from Boehringer Ingelheim. (Sagent Pharmaceuticals)

Japan’s Nichi-Iko Pharmaceutical bought Illinois-based Sagent Pharmaceuticals in 2016 to get a foothold in the U.S. Now Nichi-Iko is establishing a solid U.S. manufacturing footprint by acquiring a plant in North Carolina.

Nichi-Iko says that Sagent has bought an FDA-approved small molecule and biologics manufacturing site in Raleigh from Copenhagen, Denmark-based Xellia Pharmaceuticals. The North Carolina facility is the first U.S. plant for Tokyo-based Nichi-Iko as well as for Sagent which has traditionally relied on contractors to produce the sterile injectables it produces for clients.   

Terms of the deal were not disclosed, but Nichi-Iko said it was taking on the plant’s employees and that Schaumburg, Illinois-based Sagent will continue to supply Xellia with some of its products. Sagent will use the plant to produce some of the sterile injectables it already sells and the biosimilars Nichi-Iko has under development.  

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

“In addition to complementing our historic partner-based supply model with internal manufacturing capabilities, the Raleigh site will enable production of lyophilized formulations of our future biosimilars product offerings,” Sangent CEO Peter Kaemmerer said in a statement (pdf).

Nichi-Iko says it is one of the largest Japanese generic drugmakers with sales of about $1.5 billion. It bought Sagent in 2016 for about $735 million to move into the U.S. market and as a conduit in the U.S. for the biosimilars it is developing.

Suggested Articles

Industry watchers have been speculating about just how high Novartis would price gene therapy Zolgensma. And now, they have an answer.

The WHO’s role in part is to provide prescribing guidance without an eye on profits. What happens when that guidance is tainted by private money?

After 19 sales reps left Amgen to help Karyopharm launch a rival multiple myeloma drug, Amgen sued. Now Karyopharm wants the suit thrown out.